XERS Earnings — Xeris Biopharma Holdings, Inc. Common Stock Post-ER Performance | BigEarnings
XERS — Xeris Biopharma Holdings, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$6.16
Market Cap$1.1B
P/E88.6
52W Range$4.30 – $10.08
Next Earnings2026-08-06
About Xeris Biopharma Holdings, Inc. Common Stock
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
